Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
Due to a continuing shortage of generic versions of the antibiotic cefazolin by Nichi-Iko Pharmaceutical, shipments of 21 other products used as substitutes are being adjusted to supply existing customers on a priority basis. The situation was reported on April…
To read the full story
Related Article
- Nichi-Iko to Resume Normal Shipments of Cefazolin Starting October 1
September 17, 2020
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- Nichi-Iko to Gradually Resume Cefazolin Supply from Nov. 25
October 28, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Nichi-Iko Aims to Resume Stable Supply of Cefazolin by Year-End: Exec
May 14, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
ACADEMIA
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
- Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
- 63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…